← Human Trials & Peer-Reviewed Studies
[Psychological impact of growth hormone deficiency in adolescence: an observational study in pediatric clinical practice].
Plain-language guide to PMID 40207955 (2025): observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 24 adolescents.
Key Facts
- PMID
- 40207955
- Journal
- Recenti progressi in medicina
- Year
- 2025
- Study type
- Observational Study
- Authors
- Guerra F et al. (7 authors)
- DOI
- 10.1701/4480.44818
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as an observational study.
Present observational study aimed to examine the effects of Ghd and its treatment in outpatient adolescents, during the follow-up.
Why It Was Studied
Growth problems in children and adolescents are a frequent reason for referral to pediatric endocrinologists with the most common endocrine form of short stature being growth hormone deficiency (Ghd).
Health-related quality of life (HRQoL) is an important factor in adolescents with Ghd and should be considered in clinical practice by physicians and psychologists.
Who Took Part
According to the abstract, 24 adolescents were involved.
The age groups tagged for this paper are children and teenagers, both men and women.
The participants were approached to participate in the study at the Auxological Pediatric Ambulatory of the San Salvatore Hospital (L'Aquila).
How the Study Was Run
An observational study was conducted among 24 adolescents aged 11-18,9 years with Ghd diagnosis.
What Was Measured
Topics PubMed links to this paper include Quality of Life, Human Growth Hormone, Growth Disorders and Sex Factors.
What This Means in Plain Language
This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 24 adolescents.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2025 (Recenti progressi in medicina), a journal based in Italy.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.